As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face ...

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and ...

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a ...

Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet ...

Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption. In the third and final installment of Pharmaceutical Commerce’s video ...

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes. The complex nature of the pipeline means that equipment ...

Chase Heibel is director and general manager, controlled temperature technologies, at Thermo Fisher Scientific. Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s ...

CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates. The Centers for Medicare & Medicaid Services (CMS) ...

Four pillars frame executive dialogue: industry transformation, resilient supply networks, operationalizing policy expectations, and scaling manufacturing capacity/infrastructure to match accelerating ...